177 related articles for article (PubMed ID: 35180059)
21. A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient.
Maruki T; Ishikane M; Suzuki T; Ujiie M; Katano H; Ohmagari N
Int J Infect Dis; 2021 Dec; 113():55-57. PubMed ID: 34587536
[TBL] [Abstract][Full Text] [Related]
22. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
[TBL] [Abstract][Full Text] [Related]
23. Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 vaccine (BNT162b2 Comirnaty, Pfizer).
Zengarini C; Misciali C; Ferrari T; Dika E; La Placa M; Piraccini BM; Baraldi C
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e622-e623. PubMed ID: 35429051
[No Abstract] [Full Text] [Related]
24. Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine.
Arora P; Sardana K; Mathachan SR; Malhotra P
J Cosmet Dermatol; 2021 Nov; 20(11):3389-3390. PubMed ID: 34077622
[No Abstract] [Full Text] [Related]
25. Influenza vaccine and subsequent development of zoster.
Wei KC; Chang YC; Huang YT
Influenza Other Respir Viruses; 2023 Jan; 17(1):e13055. PubMed ID: 36114790
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
27. Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
[TBL] [Abstract][Full Text] [Related]
28. Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
Chen YC; Ho CH; Liu TH; Wu JY; Huang PY; Tsai YW; Lai CC
J Med Virol; 2023 Apr; 95(4):e28745. PubMed ID: 37185849
[TBL] [Abstract][Full Text] [Related]
29. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
30. [Multisegmental herpes zoster in a healthy 20-year-old man after COVID-19 vaccination].
Lebedeva V; Müller C; Dissemond J
Hautarzt; 2022 Mar; 73(3):220-221. PubMed ID: 35029697
[No Abstract] [Full Text] [Related]
31. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
32. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR
JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
[TBL] [Abstract][Full Text] [Related]
35. Plantar herpes zoster following heterologous recombinant adenovirus-based COVID-19 vaccine.
Ayatollahi A; Robati RM; Firooz A
J Cosmet Dermatol; 2022 Jan; 21(1):34-35. PubMed ID: 34757689
[No Abstract] [Full Text] [Related]
36. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine.
Tessas I; Kluger N
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e620-e622. PubMed ID: 34058038
[No Abstract] [Full Text] [Related]
37. Association of herpes zoster with COVID-19 vaccination: A systematic review and meta-analysis.
Chen IL; Chiu HY
J Am Acad Dermatol; 2023 Aug; 89(2):370-371. PubMed ID: 37001732
[No Abstract] [Full Text] [Related]
38. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
39. Reply to: correspondence on "Herpes Zoster and Simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis".
Gringeri M; Battini V; Cammarata G; Mosini G; Guarnieri G; Leoni C; Pozzi M; Radice S; Clementi E; Carnovale C
Expert Rev Vaccines; 2022 Aug; 21(8):1161-1162. PubMed ID: 35522022
[No Abstract] [Full Text] [Related]
40. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
